aptaTargets receives a €1.940 million grant from the Community of Madrid

19 February, 2024

aptaTargets - EIC Accelerator
aptaTargets’ therapeutic project “ApTOLL, innovative neuroprotectant to reduce brain damage in Acute Ischemic Stroke (AIS)”, which has obtained the Seal of Excellence from the European Innovation Council’s Accelerator programme, has been selected by the Community of Madrid to receive a direct grant of €1.9 million.

The Ministry of Education, Science and Universities of the Community of Madrid has assessed the scientific excellence, the social impact and the remarkable potential for success of the aptaTargets project.

The aid is part of the budget of the National Recovery Plan and Next Generation EU for the promotion of business investment in R&D&I.

The main objective of the aptaTargets project is to advance the clinical development of ApTOLL innovative therapy, with a neuroprotectant effect, which includes conducting Phase 2b studies in patients with AIS.